menu
    • menu
    [{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CDNF","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Herantis Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Herantis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Nanoform","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FINLAND","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"CDNF","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Herantis Pharma \/ Nanoform","highestDevelopmentStatusID":"7","companyTruncated":"Herantis Pharma \/ Nanoform"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Renishaw","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Cerebral Dopamine Neurotrophic Factor","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Herantis Pharma \/ Renishaw","highestDevelopmentStatusID":"7","companyTruncated":"Herantis Pharma \/ Renishaw"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Renishaw","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Cerebral Dopamine Neurotrophic Factor","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Herantis Pharma \/ Renishaw","highestDevelopmentStatusID":"7","companyTruncated":"Herantis Pharma \/ Renishaw"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FINLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Cis-UCA","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Herantis Pharma \/ Ora, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Herantis Pharma \/ Ora, Inc"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Clinical Research Services Turku - CRST Oy","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HER-096","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Herantis Pharma \/ Clinical Research Services Turku - CRST Oy","highestDevelopmentStatusID":"6","companyTruncated":"Herantis Pharma \/ Clinical Research Services Turku - CRST Oy"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Clinical Research Services Turku - CRST Ltd | BC Platforms | Medfiles Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HER-096","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Herantis Pharma \/ Clinical Research Services Turku - CRST Ltd | BC Platforms | Medfiles Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Herantis Pharma \/ Clinical Research Services Turku - CRST Ltd | BC Platforms | Medfiles Ltd"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HER-096","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Herantis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Herantis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Lymfactin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Herantis Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Herantis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Lymfactin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Herantis Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Herantis Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Herantis Pharma

    Menu

    Herantis Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HER-096

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Patients Dosed in Final Cohort of HER-096 Parkinson’s Phase 1b Trial

                            Details : HER-096 is a CDNF mimetic that has the potential to protect against the neuronal degeneration and cell death that cause the symptoms of Parkinson’s disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 13, 2025

                            Lead Product(s) : HER-096

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HER-096

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Clinical Research Services Turku - CRST Ltd | BC Platforms | Medfiles Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease

                            Details : HER-096 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 26, 2024

                            Lead Product(s) : HER-096

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Clinical Research Services Turku - CRST Ltd | BC Platforms | Medfiles Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HER-096

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Clinical Research Services Turku - CRST Oy

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Ascending Doses of HER-096 in Healthy Subjects

                            Details : HER-096 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 22, 2023

                            Lead Product(s) : HER-096

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Clinical Research Services Turku - CRST Oy

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CDNF

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Nanoform

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nanoform and Herantis sign Biologics Proof of Concept Agreement

                            Details : Nanoform and Herantis have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis’ CDNF and xCDNF therapies (Parkinson’s disease) using Nanoform’s proprietary biological nanoparticle technology.

                            Product Name : CDNF

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            December 17, 2020

                            Lead Product(s) : CDNF

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Nanoform

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CDNF

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Herantis Pharma Plc Announces Topline Results of Phase 1-2 CDNF Trial

                            Details : Topline analysis confirms positive safety and tolerability of CDNF in advanced-stage Parkinson's disease patients, with encouraging biological responses.

                            Product Name : CDNF

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 25, 2020

                            Lead Product(s) : CDNF

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cerebral Dopamine Neurotrophic Factor

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Renishaw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Stu...

                            Details : Cerebral Dopamine Neurotrophic Factor is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 14, 2018

                            Lead Product(s) : Cerebral Dopamine Neurotrophic Factor

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Renishaw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lymfactin

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE)

                            Details : Lymfactin is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphedema.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 06, 2018

                            Lead Product(s) : Lymfactin

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cerebral Dopamine Neurotrophic Factor

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Renishaw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease

                            Details : Cerebral Dopamine Neurotrophic Factor is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 28, 2017

                            Lead Product(s) : Cerebral Dopamine Neurotrophic Factor

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Renishaw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lymfactin

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema

                            Details : Lymfactin is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphedema.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 16, 2016

                            Lead Product(s) : Lymfactin

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed

                            Herantis Pharma

                            Finland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cis-UCA

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Ora, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye

                            Details : Cis-UCA is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 25, 2014

                            Lead Product(s) : Cis-UCA

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Ora, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth